Trametinib
Mekinist · MEK inhibitor
MEK inhibitor; hypertension, proteinuria, and combination-therapy AKI.
Imbruvica · Ibrut
BTK inhibitor · approved 2013 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A first-generation BTK inhibitor whose off-target kinase inhibition drives hypertension — and occasionally proteinuria, AIN or AKI.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
New or worsened hypertension is common (~26% in a real-world CLL cohort comparing it with acalabrutinib; higher with longer follow-up). AKI at CLL presentation and with tumor lysis is well described. Drug-attributable AKI from interstitial nephritis or glomerular endotheliosis is case-level.Source: Majrashi et al., Pharmacol Res Perspect 2025 (HTN 26.3%)
Hypertension over weeks to months; tumor lysis early (first cycle); glomerular/interstitial lesions case-level over weeks to months.
Distilled from: “Hypertension develops over weeks–months (can be early); tumor lysis is early (first cycle); glomerular/interstitial lesions are case-level over weeks to months.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Any-grade hypertension in 25.3% of ibrutinib-treated relapsed/refractory CLL/SLL patients (ALPINE, n=325).
Not the same figure as §01's 26%. §01 is new-onset hypertension in a matched real-world CLL cohort; this row is hypertension reported as an adverse event in the ibrutinib arm of the ALPINE trial.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Hypertension strikes: Glomerulus, Vasculature / Endothelium.
Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
Irreversible covalent Bruton tyrosine kinase (BTK) inhibitor that binds cysteine-481, shutting down B-cell receptor signaling and NF-κB–driven survival in chronic lymphocytic leukemia (CLL), mantle-cell lymphoma and Waldenström macroglobulinemia. Its off-target inhibition of other kinases (including TEC, ITK, EGFR and effects on endothelial/VEGF signaling) underlies several toxicities.
Class-level context for the major non-renal toxicities of the BTK inhibitor class.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 80,997 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
13,832 of 80,997 reports
Reported with hospitalization
26,987 of 80,997 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,355 of the 80,997 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ibrutinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Mekinist · MEK inhibitor
MEK inhibitor; hypertension, proteinuria, and combination-therapy AKI.
AK112 (Akeso/Summit) · PD-1 x VEGF bispecific antibody
Two nephrotoxic pathways in one molecule: VEGF-blockade glomerular injury plus checkpoint-inhibitor interstitial nephritis.
Sutent · VEGFR TKI
VEGFR-TKI; hypertension and proteinuria, TMA reported.
Trodelvy · Antibody-drug conjugate (Trop-2/SN-38)
Diarrhea-driven prerenal AKI; emerging direct signals.
Tevimbra · PD-1 immune checkpoint inhibitor
A PD-1 blocker whose kidney risk is the class-typical rare immune-mediated interstitial nephritis.
Yervoy · CTLA-4 checkpoint inhibitor
CTLA-4 inhibitor; immune (often granulomatous) interstitial nephritis.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.